Kura Downgraded to Hold by Stifel, Prefers Rival Syndax
Stifel Downgrades Kura Oncology(KURA.US) to Hold Rating, Cuts Target Price to $19
Stifel Downgrades Kura Oncology to Hold From Buy, Adjusts Price Target to $19 From $26
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA), Tenaya Therapeutics (TNYA) and PepGen Inc. (PEPG)
Kura Oncology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Aquestive Therapeutics (AQST)
Wedbush Reiterates Outperform on Kura Oncology, Maintains $37 Price Target
Scotiabank Reaffirms Their Hold Rating on Kura Oncology (KURA)
Buy Rating Affirmed for Kura Oncology Amid Positive Clinical and Financial Developments
Buy Rating on Kura Oncology's Ziftomenib for Its Dual Promise in Oncology and Diabetes Management
Kura Oncology Analyst Ratings
Kura Oncology Analyst Ratings
JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $32 Price Target
Kura Oncology Analyst Ratings
Buy Rating Affirmed for Kura Oncology Amidst Promising Ziftomenib Trials and Strategic Advantages
Kura Oncology Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target
HC Wainwright & Co. : The Kura Oncology (KURA.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $32.00.
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Tourmaline Bio (TRML)